Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Transcode Therapeutics Inc (RNAZ)

Transcode Therapeutics Inc (RNAZ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer PR Newswire - Mon Nov 17, 7:01AM CST

Accomplished drug development leader to advance TransCode's mission of defeating cancer through RNA innovation and translational excellence

RNAZ : 8.63 (+2.62%)
TransCode Therapeutics Completes Phase 1a Trial for TTX-MC138 Tipranks - Wed Oct 15, 7:30AM CDT

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. TransCode...

RNAZ : 8.63 (+2.62%)
TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO PR Newswire - Tue Oct 14, 7:06AM CDT

BOSTON , Oct. 14, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) announces completion of Phase 1a clinical trial with TTX-MC138, an investigational inhibitor of microRNA-10b, or...

RNAZ : 8.63 (+2.62%)
TransCode Therapeutics Acquires Polynoma and Secures Investment Tipranks - Thu Oct 9, 9:20AM CDT

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. TransCode...

RNAZ : 8.63 (+2.62%)
TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology company PR Newswire - Wed Oct 8, 7:01AM CDT

BOSTON and SAN DIEGO , Oct. 8, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) ("TransCode or the "Company") announced today that it entered into a definitive agreement to acquire...

RNAZ : 8.63 (+2.62%)
TransCode Therapeutics Amends Patent License Agreement Tipranks - Sat Oct 4, 3:42PM CDT

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. TransCode...

RNAZ : 8.63 (+2.62%)
TransCode Therapeutics (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138 Investor Brand Network - Thu May 1, 10:22AM CDT

TransCode Therapeutics (NASDAQ: RNAZ) reported continued progress in its Phase 1a trial of TTX-MC138, an RNA-based therapeutic targeting microRNA-10b in metastatic cancer. Thirteen patients have received...

RNAZ : 8.63 (+2.62%)
TransCode Therapeutics Announces 1-for-33 Reverse Stock Split Effective December 4, 2024 Quiver Quantitative, Inc. - Sat Nov 30, 2024

TransCode Therapeutics will implement a 1-for-33 reverse stock split effective December 4, 2024, to maintain Nasdaq listing requirements.Quiver AI SummaryTransCode Therapeutics, Inc. announced a 1-for-33...

RNAZ : 8.63 (+2.62%)
TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split GlobeNewswire - Fri Nov 29, 2024

RNAZ : 8.63 (+2.62%)
TransCode Therapeutics, Inc. Announces $8 Million Private Placement Agreement with Institutional Investors Quiver Quantitative, Inc. - Wed Nov 27, 2024

TransCode Therapeutics announces an $8 million private placement of common stock and warrants for general corporate purposes.Quiver AI SummaryTransCode Therapeutics, Inc. has announced a securities purchase...

RNAZ : 8.63 (+2.62%)

Barchart Exclusives

Jamie Dimon Has Long Been Sounding the Economic Alarm. After the Fed’s Latest Rate Cut, Can You Still Bank on JPMorgan Stock? Barchart - Wed Dec 10, 8:10PM CST
A nearly 5% plunge in JPM shares on Tuesday is reason for caution with the leader of U.S. bank stocks. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot